# Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

Study · id `cardio:ct-nct05888103` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05888103](<https://clinicaltrials.gov/study/NCT05888103>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05888103

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.

## Technical summary

Registry record NCT05888103. Randomized; quadruple masking; primary purpose treatment. Start 2023-07-11 (actual); primary completion 2024-04-02 (actual). Results posted on 2025-04-20.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 207 participants (enrolled count; ClinicalTrials.gov record NCT05888103, source copy `cardio:ctgov-nct05888103-2026-01-13`, retrieved 2026-10-31)
- Started: 2023-07-11 (actual) (ClinicalTrials.gov record NCT05888103, source copy `cardio:ctgov-nct05888103-2026-01-13`, retrieved 2026-10-31)
- Primary completion: 2024-04-02 (actual) (ClinicalTrials.gov record NCT05888103, source copy `cardio:ctgov-nct05888103-2026-01-13`, retrieved 2026-10-31)
- Completion: 2024-10-24 (actual) (ClinicalTrials.gov record NCT05888103, source copy `cardio:ctgov-nct05888103-2026-01-13`, retrieved 2026-10-31)
- Results first posted: 2025-04-20 (ClinicalTrials.gov record NCT05888103, source copy `cardio:ctgov-nct05888103-2026-01-13`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT05888103, source copy `cardio:ctgov-nct05888103-2026-01-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05888103-2026-01-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
- Acronym: V-Mono China
- Condition: Primary Hypercholesterolemia or Mixed Dyslipidemia
- Intervention (Drug): Inclisiran
- Intervention (Drug): Matching Placebo for Inclisiran
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: e9ad5b45a7019580f1d7d5ffcb19fdf0fd9546af1efd5a556c19b325cb4eef06
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
